Might MRD be used to adjust treatment of oncology patients? MRD negative patients have a better prognosis and survival in clinical settings. Patients’ follow-up is resource consuming and treatment is often not adjusted to tumor kinetics. MRD characterization in clinical practice is limited by current technologies due to the lack of standardization and accuracy. Access to time and cost effective MRD detection techniques is necessary in daily clinical practice. Altum has developed and validated cutting-edge technologies for genetic characterization and monitoring of cancer patients at all clinical stages of the disease, from genetic marker identification at diagnosis, MRD characterization in remission and identification of clonal dynamics at relapse.